Specific Peptide Ligand for Grb7 Signal Transduction Protein and Pancreatic Cancer Metastasis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pancreatic cancer is one of the most aggressive malignancies, with high rates of invasion and metastasis and with generally poor prognosis. We previously found that metastasis was strongly associated with the expression of growth factor receptor-bound protein 7 (Grb7), which contains a Src homology 2 (SH2) domain. In this study, we evaluated Grb7 protein as a molecular target of therapy for metastatic pancreatic cancer. METHODS: Grb7 protein expression was measured by immunohistochemistry in 36 human pancreatic cancer specimens and adjacent normal pancreatic tissue. We synthesized a nonphosphorylated peptide inhibitor that binds specifically to the SH2 domain of Grb7. Intracellular signaling was assessed by immunoprecipitation and immunoblot assays in cultured human pancreatic cancer cells. Cell migration was measured with a modified Boyden chamber method. Peritoneal metastasis of the pancreatic cancer cells was measured with a mouse model. All statistical tests were two-sided. RESULTS: We found that 22 (61%) of 36 pancreatic cancer specimens had higher levels of Grb7 protein than their corresponding normal pancreatic tissue specimens. Grb7 expression was statistically significantly different between specimens from patients without lymph node metastasis (stage N0; two of the 10 patients) and patients with lymph node metastasis (stages N1 + N2; 20 of the 26 patients) (P = .006). The Grb7 peptide inhibitor selectively blocked the interaction between Grb7 and focal adhesion kinase and blocked the phosphorylation of Grb7 protein. In vivo Grb7 peptide inhibitor statistically significantly attenuated cell migration (for control peptide, 87.5 cells migrated, 95% confidence interval [CI] = 82.6 to 92.4 cells; for Grb7 peptide, 5.7 cells migrated, 95% CI = 2.3 to 9.0 cells; P < .001) and peritoneal metastasis of the pancreatic cancer cells in a mouse model, as assessed by the number of nodules (control = 72.6 nodules, 95% CI = 55.8 to 89.4 nodules; and for Grb7 peptide = 3.2 nodules, 95% CI = 1.6 to 4.8 nodules; P < .001, t test) and their weight (control = 4.13 g, 95% CI = 3.40 to 4.86 g; Grb7 peptide = 0.19 g, 95% CI = 0.06 to 0.32 g; P < .001, t test). CONCLUSIONS: The Grb7 peptide inhibitor appears to be a promising molecularly targeted therapeutic agent against metastatic pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Cited by
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression
Selamat, S. A., Chung, B. S., Girard, L., Zhang, W., Zhang, Y., Campan, M., Siegmund, K. D., Koss, M. N., Hagen, J. A., Lam, W. L., et al. (2012) · Genome Research · doi:10.1101/gr.132662.111 · Cited by 521
Reprogramming the Translation Initiation for the Synthesis of Physiologically Stable Cyclic Peptides
Goto, Y., Ohta, A., Sako, Y., Yamagishi, Y., Murakami, H., & Suga, H. (2008) · ACS Chemical Biology · doi:10.1021/cb700233t · Cited by 275
Chu, P.-Y., Tai, Y.-L., & Shen, T.-L. (2019) · Cells · doi:10.3390/cells8050435 · Cited by 84
Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
Chan, D. W., Hui, W. W. Y., Cai, P. C. H., Liu, M. X., Yung, M. M. H., Mak, C. S. L., Leung, T. H. Y., Chan, K. K. L., & Ngan, H. Y. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052578 · Cited by 51
“For examples, the combination of Grb7 cyclic peptide, G7-18NATE, with chemo-drugs were capable of inhibiting breast cancer cell growth [47,48], or with the specific peptide ligand to suppress GRB7-mediated metastasis in pancreatic carcinoma etc [11,49].”
BackgroundSparano, J. A., Goldstein, L. J., Childs, B. H., Shak, S., Brassard, D., Badve, S., Baehner, F. L., Bugarini, R., Rowley, S., Perez, E. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3357 · Cited by 22
Metadata
- Authors
- Tanaka, S., Pero, S. C., Taguchi, K., Shimada, M., Mori, M., Krag, D. N., & Arii, S.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-05
- Volume
- 98
- Issue
- 7
- Pages
- 491-498
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W1990426099
- Cited by
- 86
- References
- 1
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific Peptide Ligand for Grb7 Signal Transduction Protein and Pancreatic Cancer Metastasis. https://app.cochat.ai/papers/10.1093/jnci/djj105
- The paper
- Tanaka, S., Pero, S. C., Taguchi, K., Shimada, M., Mori, M., Krag, D. N., & Arii, S. (2006). Specific Peptide Ligand for Grb7 Signal Transduction Protein and Pancreatic Cancer Metastasis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djj105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.